Evidence map›Paper›PMID 27112143›Full record

ArticleAnnals of clinical microbiology and antimicrobials2016

Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.

Davie Wong, Titus Wong, Marc Romney, Victor Leung

Retracted Registry-linked trialOpen access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to trial NCT05983861 (Risk Factors for Multidrug Resistant Bacteria at ICU Admission), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05983861 unknown statusnot on this mapstarted 2023, after this paper: background citation

Risk Factors for Multidrug Resistant Bacteria at ICU Admission

TypeobservationalSponsorJosé Raimundo Araujo de AzevedoRan2023 to 2025Enrolled400ConditionsMulti Drug Resistant BacteriaArmsIdentification o Multi Drug Resistant Bacteria
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Evaluation of Clinical Approach and OutcomesInfectious diseases & clinical microbiology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Davie WongPGY-V Infectious Diseases Residency Training Program, Vancouver General Hospital, University of British Columbia, D 452 Heather Pavilion, 2733 Heather Street, Vancouver, BC, V5Z 1M9, Canada. davie1985@hotmail.com.
Titus WongDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Marc RomneyDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Victor LeungDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVancomycin may be inferior to β-lactams for the empiric treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. We compared empiric β-lactams to vancomycin to assess clinical outcomes in patients with MSSA bacteremia.

methodsWe conducted a retrospective cohort study of adult inpatients with their first episode of MSSA bacteremia at two tertiary care hospitals in Vancouver, Canada, between 2007 and 2014. Exposure was either empiric β-lactam with or without vancomycin or vancomycin monotherapy. All patients received definitive treatment with cloxacillin or cefazolin. The primary outcome was 28-day mortality. Secondary outcomes were 90-day mortality, duration of bacteremia, and hospital length-of-stay. Outcomes were adjusted using multivariable logistic regression.

resultsOf 669 patients identified, 255 met inclusion criteria (β-lactam = 131, vancomycin = 124). Overall 28-day mortality was 7.06 % (n = 18). There were more cases of infective endocarditis in the β-lactam than in the vancomycin group [24 (18.3 %) vs 12 (9.7 %), p = 0.05]. Adjusted mortality at 28 days was similar between the two groups (OR 0.85; 95 % CI 0.27-2.67). The duration of bacteremia was longer in the vancomycin group (97.1 vs 70.7 h, p = 0.007). Transition to cloxacillin or cefazolin occurred within a median of 68.3 h in the vancomycin group.

conclusionsEmpiric β-lactams was associated with earlier clearance of bacteremia by a median of 1 day compared to vancomycin. Future prospective studies are needed to confirm our findings.

Indexed as

AdultAgedAged, 80 and overBacteremiabeta-LactamsFemaleHumansMaleMethicillinRetrospective StudiesStaphylococcal InfectionsStaphylococcus aureusTreatment OutcomeVancomycinbeta-LactamsMethicillinVancomycinBacteremiaBeta-lactamEmpiric therapyMethicillin-susceptibleStaphylococcus aureusVancomycin

Identifiers

PMID27112143
PMCPMC4845304
OpenAlexW2343935142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.